Metabolomic profiling of pancreatic adenocarcinoma reveals fundamental clinical features
J. L. IOVANNA, A. El kaoutari, N. Fraunhoffer…·N. J. Dusetti
This study identifies a metabolic signature in pancreatic adenocarcinoma that predicts clinical outcomes and drug resistance, suggesting metabolic targeting as a therapeutic strategy.